Drug intelligence / Profile preview

IM-01

Development stage: Phase 2
Lead developer: ImmuniMed
Modality: Antibody-Based Therapeutics

Overview

IM-01 is an investigational egg-derived polyclonal antibody developed by ImmuniMed Inc. for the treatment of mild-moderate Clostridium difficile infection (CDI). It functions by reacting with C. difficile toxin, C. difficile bacteria, and spores, thereby neutralizing the toxin and inhibiting the growth of both vegetative forms and spores of C. difficile.

Brand names: CDiffFYX
Other names: egg-derived polyclonal antibodiesegg-derived anti-C. difficile polyclonal antibodies

Targets

TcdA (Clostridioides difficile toxin A)TcdB (Clostridioides difficile large clostridial toxin family)Clostridioides difficile spores

Beyond the preview

Go deeper on IM-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IM-01.

Explore the full profile